Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,023 | -8,670 | -48,818 | -39,494 | -26,218 |
| Depreciation Amortization | 405 | 216 | 790 | 591 | 391 |
| Other Working Capital | 1,520 | -298 | -3,149 | -3,857 | -4,887 |
| Other Operating Activity | 2,752 | 1,378 | 3,842 | 2,915 | 1,994 |
| Operating Cash Flow | $-15,346 | $-7,374 | $-47,335 | $-39,845 | $-28,720 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -11 | -11 | -153 | -153 | -123 |
| Investing Cash Flow | $-11 | $-11 | $-153 | $-153 | $-123 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5 | -2 | -4 | -3 | -2 |
| Common Stock Issued | 24,727 | 14,770 | 14,874 | 13,681 | 10,820 |
| Financing Cash Flow | $24,722 | $14,768 | $14,870 | $13,678 | $10,818 |
| Beginning Cash Position | 76,990 | 76,990 | 109,608 | 109,608 | 109,608 |
| End Cash Position | 86,355 | 84,373 | 76,990 | 83,288 | 91,583 |
| Net Cash Flow | $9,365 | $7,383 | $-32,618 | $-26,320 | $-18,025 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,346 | -7,374 | -47,335 | -39,845 | -28,720 |
| Capital Expenditure | -11 | -11 | -153 | -153 | -123 |
| Free Cash Flow | -15,357 | -7,385 | -47,488 | -39,998 | -28,843 |